

INDICATIVE MASTER LIST OF ELIGIBLE ITEMS, AND AGREED LIST OF ACCEPTABLE EXPENDITURE ITEMS ('POSITIVE LIST'), FOR ADB-FINANCING UNDER THE RAPID RESPONSE COMPONENT

The eligible items agreed for financing will include:

- (i) Advance market commitments and/or payments or procurement costs for vaccines acquired through the COVID-19 Vaccines Global Access (COVAX) facility.
- (ii) Vaccines that will be procured directly from vaccine manufacturers or distributors provided they meet any of the eligibility criteria outlined in the linked document, Eligibility Criteria for Use of Funds under the Rapid Response Component.¹
 - a) The vaccines that will be potentially financed by Asian Development Bank (ADB) are those manufactured by AstraZeneca/Oxford University, Johnson&Johnson/Janssen, and Covovax (Novavax licensed to and manufactured by the Serum Institute of India), provided they meet one of the eligibility criteria.
 - b) Other vaccines being explored for procurement which may also be financed by ADB are vaccines manufactured by Moderna and Pfizer/BioNTec. Other vaccines being considered for procurement which may be financed by ADB if they meet one of the eligibility criteria are SinoVac, Gamaleya and others.
- (iii) Advance payments for vaccines that meet one of the eligibility criteria, and that will be procured directly from vaccine manufacturers and distributors (see item [ii]).
- (iv) International logistics and related services required for the transportation of eligible vaccines to designated delivery points in the Philippines.
- (v) Indirect management fees, with reasonable percentage normally below 10% of the loan amount managed, charged as required by the UN agencies' financial regulations or similar authoritative guidelines.

¹ Eligibility criteria for use of funds under the rapid response component (accessible from the list of linked documents in Appendix 2 of the report and recommendation of the President).